Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcel Verheij

Showing results (111-120 of 182) with videos related to

Pageof 19
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 23, 2016
Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximabIris Walraven, Michel van den Heuvel, Judi van Diessen, et al.
Cancers|April 3, 2019
Genetic Factors Associated with a Poor Outcome in Head and Neck Cancer Patients Receiving Definitive ChemoradiotherapyDavid M Vossen, Caroline V M Verhagen, Martijn van der Heijden, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|March 10, 2025
The role of adjuvant chemotherapy in rectal cancer: A nationwide cohort study from the NetherlandsAaya Darai, Tijmen Koëter, Felice N van Erning, et al.
Anti-Cancer Drugs|November 29, 2007
Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: antiangiogenic properties of a new class of antitumor agentsShuraila F Zerp, Stefan R Vink, Gerald A Ruiter, et al.
Blood|May 8, 2007
In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphomaLaurent Knoops, Rick Haas, Sanne de Kemp, et al.
BMC Cancer|February 26, 2013
Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancerJolien Heukelom, Olga Hamming, Harry Bartelink, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 19, 2015
Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cellsCaroline V M Verhagen, Rosemarie de Haan, Floor Hageman, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 13, 2007
99mTc Hynic-rh-Annexin V scintigraphy for in vivo imaging of apoptosis in patients with head and neck cancer treated with chemoradiotherapyFrank J P Hoebers, Marina Kartachova, Josien de Bois, et al.
International Journal of Radiation Oncology, Biology, Physics|September 18, 2012
Targeted radiosensitization by the Chk1 inhibitor SAR-020106Gerben R Borst, Martin McLaughlin, Joan N Kyula, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 8, 2024
Using a modified Delphi procedure to select a PRO-CTCAE-based subset for patient-reported symptomatic toxicity monitoring in rectal cancer patientsYvonne M Geurts, Femke Peters, Esther Feldman, et al.
Pageof 19

Showing results (111-120 of 182) with videos related to

Sort By:
Pageof 19
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 23, 2016
Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximabIris Walraven, Michel van den Heuvel, Judi van Diessen, et al.
Cancers|April 3, 2019
Genetic Factors Associated with a Poor Outcome in Head and Neck Cancer Patients Receiving Definitive ChemoradiotherapyDavid M Vossen, Caroline V M Verhagen, Martijn van der Heijden, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|March 10, 2025
The role of adjuvant chemotherapy in rectal cancer: A nationwide cohort study from the NetherlandsAaya Darai, Tijmen Koëter, Felice N van Erning, et al.
Anti-Cancer Drugs|November 29, 2007
Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: antiangiogenic properties of a new class of antitumor agentsShuraila F Zerp, Stefan R Vink, Gerald A Ruiter, et al.
Blood|May 8, 2007
In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphomaLaurent Knoops, Rick Haas, Sanne de Kemp, et al.
BMC Cancer|February 26, 2013
Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancerJolien Heukelom, Olga Hamming, Harry Bartelink, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 19, 2015
Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cellsCaroline V M Verhagen, Rosemarie de Haan, Floor Hageman, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 13, 2007
99mTc Hynic-rh-Annexin V scintigraphy for in vivo imaging of apoptosis in patients with head and neck cancer treated with chemoradiotherapyFrank J P Hoebers, Marina Kartachova, Josien de Bois, et al.
International Journal of Radiation Oncology, Biology, Physics|September 18, 2012
Targeted radiosensitization by the Chk1 inhibitor SAR-020106Gerben R Borst, Martin McLaughlin, Joan N Kyula, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 8, 2024
Using a modified Delphi procedure to select a PRO-CTCAE-based subset for patient-reported symptomatic toxicity monitoring in rectal cancer patientsYvonne M Geurts, Femke Peters, Esther Feldman, et al.
Pageof 19